Chemomab Therapeutics Ltd - Company Profile
Powered by 
All the sales intelligence you need on Chemomab Therapeutics Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Chemomab Therapeutics Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Chemomab Therapeutics Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Chemomab Therapeutics Ltd (Chemomab), formerly Anchiano Therapeutics Ltd, is a clinical stage biopharmaceutical company. It focuses on the discovery, development, and commercialization of therapies for the unmet needs of fibrotic and inflammatory diseases. The company's lead clinical candidate CM-101, is a first-in-class monoclonal antibody that targets CCL24. Chemomab is actively advancing CM-101 into phase II studies to treat patients with liver, skin, and lung fibrosis. The company operates subsidiaries in Israel and Delaware. Chemomab is headquartered in Tel Aviv-Yafo, Tel Aviv, Israel.
Headquarters
Israel
Address
6 Habarzel Street, Building C, 10th Floor, Tel Aviv, 6971010
Website
www.chemomab.com
Telephone
972 77 3310156
No of Employees
12
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CMMB (NASD)
EPS
XYZ
Net Income (2024)
XYZ
35.5%
(2024 vs 2023)
Market Cap*
$10.7M
* As of and is in US$
Chemomab Therapeutics Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| CM-101 - for Primary Sclerosing Cholangitis (PSC) |
| CM-101 - for Systemic Sclerosis (SSc) |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Patent Grant | In February, the company was granted new patents for CM-101 from the patent offices in Brazil and Israel. |
| 2023 | Regulatory Approval | In November, the company received Fast Track designation from the U.S. Food and Drug Administration (FDA) for CM-101 for the treatment in adult patients of primary sclerosing cholangitis (PSC), a fibrotic liver disease that can result in liver transplant, cancer and early death. |
| 2023 | Regulatory Approval | In February, the company’s investigational drug CM-101 has received the US Food and Drug Administration (FDA) clearance of Phase II trials for systemic sclerosis (SSc) |
Competitor Comparison
| Key Parameters | Chemomab Therapeutics Ltd | Johnson & Johnson | Sanofi | Boehringer Ingelheim International GmbH | Ipsen SA |
|---|---|---|---|---|---|
| Headquarters | Israel | United States of America | France | Germany | France |
| City | Tel Aviv | New Brunswick | Paris | Ingelheim am Rhein | Paris |
| State/Province | Tel Aviv | New Jersey | Ile-de-France | Rheinland-Pfalz | Ile-de-France |
| No. of Employees | 12 | 138,200 | 76,493 | 54,300 | 5,535 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Nissim Darvish | Chairman | Executive Board | 2023 | 59 |
| Adi Mor, PhD | Director; Chief Scientific Officer; Chief Executive Officer | Executive Board | 2011 | 43 |
| Sigal Fattal | Chief Financial Officer | Senior Management | 2021 | 54 |
| Jack Lawler | Chief Development Officer | Senior Management | 2025 | - |
| David M. Weiner, MD | Chief Medical Officer - Interim | Senior Management | 2025 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer